

Special Issue

Antibody–Drug Conjugates (ADC)

Message from the Guest Editors

Antibody Drug Conjugates (ADC)s made of antibodies chemically linked to toxic payloads represent one of the emerging frontiers of cancer therapy, and their usefulness in clinics has continuously increased over the last 10 years. At the moment there are seven different formulations on the market: they differ for the target, the type of antibody, the linker structure and finally the nature of the payload. Notwithstanding the improvement of these bio-based drugs, there are still several critical issues to be solved, including stability, decreasing of the off-target toxicity, site-selective conjugation and engineering of the antibody molecule. This volume will approach innovation in this field, including the discovery of new targets for the development of more specific, highly penetrating and efficient ADC(s). We encourage your contribution with the aim of involving top scientist in describing more recent achievements, and with the hope that Paul Ehrlich's vision will soon become reality.

Guest Editors

Prof. Stefano Iacobelli

1. Department of Gynecology and Obstetrics, Catholic University, 00168 Rome, Italy
2. MediaPharma Srl, Via Colonneta, 50/A, 66100 Chieti, Italy

Prof. Dr. Rodolfo Ippoliti

Department of Life, Health and Environmental Sciences, University of L'Aquila, 67100 L'Aquila, Italy

Deadline for manuscript submissions

closed (28 February 2021)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/45045

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).